Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Receptor-binding domain as a target for developing SARS vaccines</title>
<author><name sortKey="Zhu, Xiaojie" sort="Zhu, Xiaojie" uniqKey="Zhu X" first="Xiaojie" last="Zhu">Xiaojie Zhu</name>
<affiliation><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Liu, Qi" sort="Liu, Qi" uniqKey="Liu Q" first="Qi" last="Liu">Qi Liu</name>
<affiliation><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3">Department of Medical Microbiology and Immunology, School of Basic Medicine, Dali University, Dali, China</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<affiliation><nlm:aff id="aff2">Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA;</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name>
<affiliation><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<affiliation><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2">Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA;</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">23977435</idno>
<idno type="pmc">3747534</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747534</idno>
<idno type="RBID">PMC:3747534</idno>
<idno type="doi">10.3978/j.issn.2072-1439.2013.06.06</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">001668</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001668</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Receptor-binding domain as a target for developing SARS vaccines</title>
<author><name sortKey="Zhu, Xiaojie" sort="Zhu, Xiaojie" uniqKey="Zhu X" first="Xiaojie" last="Zhu">Xiaojie Zhu</name>
<affiliation><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Liu, Qi" sort="Liu, Qi" uniqKey="Liu Q" first="Qi" last="Liu">Qi Liu</name>
<affiliation><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3">Department of Medical Microbiology and Immunology, School of Basic Medicine, Dali University, Dali, China</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<affiliation><nlm:aff id="aff2">Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA;</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name>
<affiliation><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<affiliation><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2">Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA;</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Thoracic Disease</title>
<idno type="ISSN">2072-1439</idno>
<idno type="eISSN">2077-6624</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>A decade ago, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) caused a global pandemic with a mortality rate of 10%. Reports of recent outbreaks of a SARS-like disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV) have raised serious concerns of a possible reemergence of SARS-CoV, either by laboratory escape or the presence of a natural reservoir. Therefore, the development of effective and safe SARS vaccines is still needed. Based on our previous studies, we believe that the receptor-binding domain (RBD) in the S1 subunit of the SARS-CoV spike (S) protein is the most important target for developing a SARS vaccine. In particular, RBD of S protein contains the critical neutralizing domain (CND), which is able to induce highly potent neutralizing antibody response and cross-protection against divergent SARS-CoV strains. Furthermore, a RBD-based subunit vaccine is expected to be safer than other vaccines that may induce Th2-type immunopathology. This review will discuss key advances in the development of RBD-based SARS vaccines and the possibility of using a similar strategy to develop vaccines against MERS-CoV.</p>
</div>
</front>
</TEI>
<pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Thorac Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">J Thorac Dis</journal-id>
<journal-id journal-id-type="publisher-id">JTD</journal-id>
<journal-title-group><journal-title>Journal of Thoracic Disease</journal-title>
</journal-title-group>
<issn pub-type="ppub">2072-1439</issn>
<issn pub-type="epub">2077-6624</issn>
<publisher><publisher-name>Pioneer Bioscience Publishing Company</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">23977435</article-id>
<article-id pub-id-type="pmc">3747534</article-id>
<article-id pub-id-type="publisher-id">jtd-05-S2-S142</article-id>
<article-id pub-id-type="doi">10.3978/j.issn.2072-1439.2013.06.06</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Receptor-binding domain as a target for developing SARS vaccines</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Zhu</surname>
<given-names>Xiaojie</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Liu</surname>
<given-names>Qi</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Du</surname>
<given-names>Lanying</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Lu</surname>
<given-names>Lu</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Jiang</surname>
<given-names>Shibo</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup>
</xref>
</contrib>
<aff id="aff1"><label>1</label>
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</aff>
<aff id="aff2"><label>2</label>
Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA;</aff>
<aff id="aff3"><label>3</label>
Department of Medical Microbiology and Immunology, School of Basic Medicine, Dali University, Dali, China</aff>
</contrib-group>
<author-notes><corresp id="cor1">Corresponding to: Shibo Jiang. 130 Dong An Road, Building #13, Xuhui District, Shanghai 200032, China. Email: <email xlink:href="shibojiang@fudan.edu.cn">shibojiang@fudan.edu.cn</email>
.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub"><month>8</month>
<year>2013</year>
</pub-date>
<pmc-comment>Fake ppub date generated by PMC from publisher
pub-date/@pub-type='epub-ppub' </pmc-comment>
<pub-date pub-type="ppub"><month>8</month>
<year>2013</year>
</pub-date>
<volume>5</volume>
<issue>Suppl 2</issue>
<fpage>S142</fpage>
<lpage>S148</lpage>
<history><date date-type="received"><day>16</day>
<month>5</month>
<year>2013</year>
</date>
<date date-type="accepted"><day>06</day>
<month>6</month>
<year>2013</year>
</date>
</history>
<permissions><copyright-statement>2013 Pioneer Bioscience Publishing Company. All rights reserved.</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder>Pioneer Bioscience Publishing Company.</copyright-holder>
</permissions>
<abstract><p>A decade ago, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) caused a global pandemic with a mortality rate of 10%. Reports of recent outbreaks of a SARS-like disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV) have raised serious concerns of a possible reemergence of SARS-CoV, either by laboratory escape or the presence of a natural reservoir. Therefore, the development of effective and safe SARS vaccines is still needed. Based on our previous studies, we believe that the receptor-binding domain (RBD) in the S1 subunit of the SARS-CoV spike (S) protein is the most important target for developing a SARS vaccine. In particular, RBD of S protein contains the critical neutralizing domain (CND), which is able to induce highly potent neutralizing antibody response and cross-protection against divergent SARS-CoV strains. Furthermore, a RBD-based subunit vaccine is expected to be safer than other vaccines that may induce Th2-type immunopathology. This review will discuss key advances in the development of RBD-based SARS vaccines and the possibility of using a similar strategy to develop vaccines against MERS-CoV.</p>
</abstract>
<kwd-group kwd-group-type="author"><title>KEY WORDS </title>
<kwd>Virus</kwd>
<kwd>severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV)</kwd>
<kwd>receptor-binding domain (RBD)</kwd>
<kwd>spike protein</kwd>
<kwd>vaccine</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0016680 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0016680 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Pmc |étape= Corpus |type= RBID |clé= |texte= }}
This area was generated with Dilib version V0.6.33. |